查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1098717

人免疫力缺乏病毒(HIV)治療藥的全球市場:佔有率，規模，趨勢，產業分析報告，各流通管道(醫院藥局，零售藥局，線上藥局，其他)，各醫藥品分類，各地區，各市場區隔預測(2022年～2030年)

Human Immunodeficiency Virus (HIV) Drugs Market Share, Size, Trends, Industry Analysis Report, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others); By Drug Class; By Region; Segment Forecast, 2022 - 2030
出版日期: | 出版商: Polaris Market Research | 英文 111 Pages | 商品交期: 最快1-2個工作天內

價格

全球人免疫力缺乏病毒(HIV)治療藥的市場規模，預計到2023年達到474億8,000萬美元。

本報告提供全球人免疫力缺乏病毒(HIV)治療藥市場調查，市場概要，市場規模和預測，趨勢，成長要素及阻礙因素，各流通管道、醫藥品分類、地區等的分析，再加上企業簡介等資訊。

目錄

第1章 簡介

  • 報告的說明
    • 調查的目的
    • 市場範圍
    • 前提條件
  • 相關利益者

第2章 摘要整理

  • 市場概況

第3章 調查手法

  • 概要
    • 資料探勘
  • 資訊來源
    • 一級資訊來源
    • 二級資訊來源

第4章 全球人免疫力缺乏病毒(HIV)治療藥市場洞察

  • 人免疫力缺乏病毒(HIV)治療藥市場-產業的概述
  • 人免疫力缺乏病毒(HIV)治療藥市場動態
    • 推動要素和機會
    • 阻礙因素與課題
  • 波特的五力分析
    • 供給企業談判力
    • 新加入廠商的威脅
    • 買方議價能力
    • 替代威脅
    • 現有企業間的競爭
  • 大環境分析
  • 人免疫力缺乏病毒(HIV)治療藥產業趨勢
  • 價值鏈分析
  • COVID-19影響分析

第5章 全球人免疫力缺乏病毒(HIV)治療藥市場:各醫藥品分類

  • 主要調查結果
  • 簡介
    • 全球人免疫力缺乏病毒(HIV)治療藥，各醫藥品分類(2018年～2030年)
  • 核苷逆轉錄酵素抑制劑
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，核苷逆轉錄酵素抑制劑，各地區(2018年～2030年)
  • 多種類組合產品
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，各多種類組合產品，各地區(2018年～2030年)
  • 蛋白分解酵素抑制劑
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，各蛋白分解酵素抑制劑，各地區(2018年～2030年)
  • HIV整合酶鏈轉移抑制劑
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，各HIV整合酶鏈轉移抑制劑，各地區(2018年～2030年)
  • 非核苷逆轉錄酵素抑制劑
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，各非核苷系逆轉錄酵素抑制劑，各地區(2018年～2030年)
  • 侵入抑制劑-CCR5一起受體拮抗劑
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，各侵入抑制劑-CCR5共受體拮抗劑，各地區(2018年～2030年)
  • 融合抑制劑
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，各融合抑制劑，各地區(2018年～2030年)
  • 其他
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，其他，各地區(2018年～2030年)

第6章 全球人免疫力缺乏病毒(HIV)治療藥市場:各流通管道

  • 主要調查結果
  • 簡介
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，各流通管道(2018年～2030年)
  • 醫院藥局
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，醫院藥局，各地區(2018年～2030年)
  • 零售藥局
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，零售藥局，各地區(2018年～2030年)
  • 線上藥局
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，線上藥局，各地區(2018年～2030年)
  • 其他
    • 全球人免疫力缺乏病毒(HIV)治療藥市場，其他，各地區(2018年～2030年)

第7章 全球人免疫力缺乏病毒(HIV)治療藥市場:各地區

  • 主要調查結果
  • 簡介
    • 人免疫力缺乏病毒(HIV)治療藥市場評估，各地區(2018年～2030年)
  • 人免疫力缺乏病毒(HIV)治療藥市場-北美
    • 北美:人免疫力缺乏病毒(HIV)治療藥市場，各流通管道(2018年～2030年)
    • 北美:人免疫力缺乏病毒(HIV)治療藥市場，各醫藥品分類(2018年～2030年)
    • 人免疫力缺乏病毒(HIV)治療藥市場-美國
    • 人免疫力缺乏病毒(HIV)治療藥市場-加拿大
  • 人免疫力缺乏病毒(HIV)治療藥市場-歐洲
    • 歐洲:人免疫力缺乏病毒(HIV)治療藥市場，各流通管道(2018年～2030年)
    • 歐洲:人免疫力缺乏病毒(HIV)治療藥市場，各醫藥品分類(2018年～2030年)
    • 人免疫力缺乏病毒(HIV)治療藥市場-英國
    • 人免疫力缺乏病毒(HIV)治療藥市場-法國
    • 人免疫力缺乏病毒(HIV)治療藥市場-德國
    • 人免疫力缺乏病毒(HIV)治療藥市場-義大利
    • 人免疫力缺乏病毒(HIV)治療藥市場-西班牙
    • 人免疫力缺乏病毒(HIV)治療藥市場-荷蘭
    • 人免疫力缺乏病毒(HIV)治療藥市場-俄羅斯
  • 人免疫力缺乏病毒(HIV)治療藥市場-亞太地區
    • 亞太地區:人免疫力缺乏病毒(HIV)治療藥市場，各流通管道(2018年～2030年)
    • 亞太地區:人免疫力缺乏病毒(HIV)治療藥市場，各醫藥品分類(2018年～2030年)
    • 人免疫力缺乏病毒(HIV)治療藥市場-中國
    • 人免疫力缺乏病毒(HIV)治療藥市場-印度
    • 人免疫力缺乏病毒(HIV)治療藥市場-馬來西亞
    • 人免疫力缺乏病毒(HIV)治療藥市場-日本
    • 人免疫力缺乏病毒(HIV)治療藥市場-印尼
    • 人免疫力缺乏病毒(HIV)治療藥市場-韓國
  • 人免疫力缺乏病毒(HIV)治療藥市場-中東及非洲
    • 中東、非洲:人免疫力缺乏病毒(HIV)治療藥市場，各流通管道(2018年～2030年)
    • 中東、非洲:人免疫力缺乏病毒(HIV)治療藥市場，各醫藥品分類(2018年～2030年)
    • 人免疫力缺乏病毒(HIV)治療藥市場-沙烏地阿拉伯
    • 人免疫力缺乏病毒(HIV)治療藥市場-阿拉伯聯合大公國
    • 人免疫力缺乏病毒(HIV)治療藥市場-以色列
    • 人免疫力缺乏病毒(HIV)治療藥市場-南非
  • 人免疫力缺乏病毒(HIV)治療藥市場-南美
    • 南美:人免疫力缺乏病毒(HIV)治療藥市場，各流通管道(2018年～2030年)
    • 南美:人免疫力缺乏病毒(HIV)治療藥市場，各醫藥品分類(2018年～2030年)
    • 人免疫力缺乏病毒(HIV)治療藥市場-墨西哥
    • 人免疫力缺乏病毒(HIV)治療藥市場-巴西
    • 人免疫力缺乏病毒(HIV)治療藥市場-阿根廷

第8章 競爭情形

  • 擴大、收購分析
    • 擴大
    • 收購
  • 夥伴關係/合作/契約/展示會

第9章 企業簡介

  • Boehringer Ingelheim
  • Cipla Limited
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck
  • Pfizer Inc.
  • Roche Ltd.
  • Teva Pharmaceutical Industries Ltd
Product Code: PM1110

The global Human Immunodeficiency Virus (HIV) drugs market size is expected to reach USD 47.48 billion by 20230 according to a new study by Polaris Market Research. The report "Human Immunodeficiency Virus (HIV) Drugs Market Share, Size, Trends, Industry Analysis Report, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others); By Drug Class; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Factors such as rising FDA approvals by the governments for HIV treatment across the globe are driving the industry growth during the forecast period. For instance, in December 2021, Apretude was licensed by the US Food and Drug Administration for pre-exposure prophylaxis (PrEP) in at-risk adults and youth weighing at least 35 kg to minimize the risk of sexually transmitted HIV. In January 2021, Cabenuva was approved by the US Food and Drug Administration for the diagnosis of human immunodeficiency virus type 1 (HIV-1) infectious disease in adults who are virologically suppressed on a secure antiretroviral treatment plan, have no history of therapeutic failure, and have no suspected or confirmed resistance towards either cabotegravir or rilpivirine.

Moreover, increased research activities will develop customized prospects for the industry to develop throughout the forecast period. Advancements in medical technology increase public and private sector attempt to raise awareness, and increased government financing will all contribute to the growth of the human immunodeficiency virus drugs industry. Other reasons, such as an increase in consumption of effective medicines and a rising acceptance rate for early genetic counseling, would have a positive impact on the growth rate of the industry. Furthermore, the rise of the industry will be fueled by increased disposable income, an increase in the number of occurrences of seizures, and a shift in lifestyle.

The hospital pharmacies segment accounted for the leading share in the industry. The category is expanding due to an increase in patient visits to hospitals for HIV drug treatment. In addition, rising sales of recommended antiretroviral medications for HIV therapy from hospital pharmacies would drive segmental growth.

Market players such as Roche Ltd., Boehringer Ingelheim, GlaxoSmithKline plc., Gilead Sciences, Inc., Johnson & Johnson, Merck, Pfizer Inc., Cipla Limited, and Teva Pharmaceutical Industries Ltd. are key players operating in the industry. In March 2021, Merck and Gilead signed a cooperation agreement to commercialize HIV therapy. This two-drug combination includes Gilead's "lenacapavir" and Merck's islatravir.

Polaris Market Research has segmented the Human Immunodeficiency Virus (HIV) drugs market report based on drug class, distribution channel, and region:

Human Immunodeficiency Virus (HIV) Drugs, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Nucleoside Reverse Transcriptase Inhibitors

Multi-Class Combination Products

Protease Inhibitors

HIV Integrase Strand Transfer Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Entry Inhibitors - CCR5 Co-Receptor Antagonist

Fusion Inhibitors

Others

Human Immunodeficiency Virus (HIV) Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Human Immunodeficiency Virus (HIV) Drugs, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Russia

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Human Immunodeficiency Virus (HIV) Drugs Market Insights

  • 4.1. Human Immunodeficiency Virus (HIV) Drugs Market - Industry Snapshot
  • 4.2. Human Immunodeficiency Virus (HIV) Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. A significant rise in number of HIV population worldwide
      • 4.2.1.2. Increasing R&D in the area of HIV infection
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Human Immunodeficiency Virus (HIV) Drugs Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Human Immunodeficiency Virus (HIV) Drugs, by Drug Class, 2018 - 2030 (USD Billion)
  • 5.3. Nucleoside Reverse Transcriptase Inhibitors
    • 5.3.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Nucleoside Reverse Transcriptase Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Multi-Class Combination Products
    • 5.4.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Multi-Class Combination Products, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Protease Inhibitors
    • 5.5.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Protease Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.6. HIV Integrase Strand Transfer Inhibitors
    • 5.6.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by HIV Integrase Strand Transfer Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 5.7.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Non-Nucleoside Reverse Transcriptase Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.8. Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 5.8.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Entry Inhibitors - CCR5 Co-Receptor Antagonist, by Region, 2018 - 2030 (USD Billion)
  • 5.9. Fusion Inhibitors
    • 5.9.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Fusion Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.10. Others
    • 5.10.1. Global Other Human Immunodeficiency Virus (HIV) Drugs Market, by Region, 2018 - 2030 (USD Billion)

6. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Other Human Immunodeficiency Virus (HIV) Drugs Market, by Region, 2018 - 2030 (USD Billion)

7. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Human Immunodeficiency Virus (HIV) Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Human Immunodeficiency Virus (HIV) Drugs Market - North America
    • 7.3.1. North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.3.3. Human Immunodeficiency Virus (HIV) Drugs Market - U.S.
      • 7.3.3.1. U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.3.4. Human Immunodeficiency Virus (HIV) Drugs Market - Canada
      • 7.3.4.1. Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.4. Human Immunodeficiency Virus (HIV) Drugs Market - Europe
    • 7.4.1. Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.3. Human Immunodeficiency Virus (HIV) Drugs Market - UK
      • 7.4.3.1. UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.4. Human Immunodeficiency Virus (HIV) Drugs Market - France
      • 7.4.4.1. France: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.5. Human Immunodeficiency Virus (HIV) Drugs Market - Germany
      • 7.4.5.1. Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.6. Human Immunodeficiency Virus (HIV) Drugs Market - Italy
      • 7.4.6.1. Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.7. Human Immunodeficiency Virus (HIV) Drugs Market - Spain
      • 7.4.7.1. Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.8. Human Immunodeficiency Virus (HIV) Drugs Market - Netherlands
      • 7.4.8.1. Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.9. Human Immunodeficiency Virus (HIV) Drugs Market - Russia
      • 7.4.9.1. Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.5. Human Immunodeficiency Virus (HIV) Drugs Market - Asia Pacific
    • 7.5.1. Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.3. Human Immunodeficiency Virus (HIV) Drugs Market - China
      • 7.5.3.1. China: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.4. Human Immunodeficiency Virus (HIV) Drugs Market - India
      • 7.5.4.1. India: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.5. Human Immunodeficiency Virus (HIV) Drugs Market - Malaysia
      • 7.5.5.1. Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.6. Human Immunodeficiency Virus (HIV) Drugs Market - Japan
      • 7.5.6.1. Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.7. Human Immunodeficiency Virus (HIV) Drugs Market - Indonesia
      • 7.5.7.1. Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.8. Human Immunodeficiency Virus (HIV) Drugs Market - South Korea
      • 7.5.8.1. South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.6. Human Immunodeficiency Virus (HIV) Drugs Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.3. Human Immunodeficiency Virus (HIV) Drugs Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.4. Human Immunodeficiency Virus (HIV) Drugs Market - UAE
      • 7.6.4.1. UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.5. Human Immunodeficiency Virus (HIV) Drugs Market - Israel
      • 7.6.5.1. Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.6. Human Immunodeficiency Virus (HIV) Drugs Market - South Africa
      • 7.6.6.1. South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.7. Human Immunodeficiency Virus (HIV) Drugs Market - Latin America
    • 7.7.1. Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.7.3. Human Immunodeficiency Virus (HIV) Drugs Market - Mexico
      • 7.7.3.1. Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.7.4. Human Immunodeficiency Virus (HIV) Drugs Market - Brazil
      • 7.7.4.1. Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.7.5. Human Immunodeficiency Virus (HIV) Drugs Market - Argentina
      • 7.7.5.1. Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Boehringer Ingelheim
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Cipla Limited
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. GlaxoSmithKline plc
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Gilead Sciences, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Johnson & Johnson
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Merck
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Pfizer Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Roche Ltd.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Teva Pharmaceutical Industries Ltd
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development

List of Tables

  • Table 1 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 2 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 3 Human Immunodeficiency Virus (HIV) Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 4 North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 5 North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 6 U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 7 U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 8 Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 9 Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 10 Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 11 Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 12 UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 13 UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 14 France: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 15 France: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 16 Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 17 Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 18 Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 19 Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 20 Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 21 Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 22 Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 23 Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 24 Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 25 Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 26 Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 27 Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 28 China: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 29 China: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 30 India: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 31 India: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 32 Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 33 Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 34 Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 35 Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 36 Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 37 Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 38 South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 39 South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 40 Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 41 Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 42 Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 43 Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 44 UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 45 UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 46 Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 47 Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 48 South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 49 South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 50 Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 51 Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 52 Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 53 Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 54 Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 55 Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 56 Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 57 Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)

List of Figures

Figure 1 Global Human Immunodeficiency Virus (HIV) Drugs Market, 2018 - 2030 (USD Billion)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top-Down & Bottom-Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Distribution Channel

Figure 7 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2021 & 2030 (USD Billion)

Figure 8 Market by Drug Class

Figure 9 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2021 & 2030 (USD Billion)

Figure 10 Human Immunodeficiency Virus (HIV) Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 11 Strategic Analysis - Human Immunodeficiency Virus (HIV) Drugs Market